Home Eric Rosenthal Reports

Eric Rosenthal Reports

Why Were Top HHS Officials’ Interviews Thwarted by Their Press Offices?

What happens when senior government health officials personally agree to be interviewed by a journalist and then their respective press offices continue to play delaying games with the actual scheduling? The original planned informational articles can change focus from sharing insights into important research initiatives to exposing seemingly obstructionist and controlling public relations operations that seek to cherry pick what...

Dr. Brawley Goes to Baltimore…and Washington

The latest chapter in Otis W. Brawley, MD’s illustrious career in cancer prevention and control commenced earlier this month when he began his tenure as a Bloomberg Distinguished Professor at Johns Hopkins University in Baltimore. During an exclusive interview with Onco’Zine, Brawley, 59, followed up on his promise in November to share information about what he then termed as a...

Jose Baselga Resigns as Co-Editor-in-Chief of Cancer Discovery

More than 100 days after the New York Times and ProPublica first revealed that Jose Baselga, MD, Ph.D, had failed to disclose millions of dollars in payments from industry, the American Association for Cancer Research (AACR) announced that Baselga, a former society president from 2015-2016, had resigned as one of the editors-in-chief of Cancer Discovery, referred to several times...

Professional Societies Disclose Their Disclosure Policies, But Why Won’t Some Discuss Them?

Last month I wrote about “How Meaningful Will Changes Be to Ethical Guidelines Following Jose Baselga’s Fall?” The article dealt with the fallout of Baselga’s failure to disclose millions of dollars he had received from industry, and his subsequent resignation as Memorial Sloan Kettering Cancer Center’s physician-in-chief as well as from a number of corporate boards. The disclosure issue had initially...

Otis Brawley Discusses Life After Leaving the American Cancer Society

When Otis W. Brawley, MD — who had served as the face of the American Cancer Society (ACS) for the past 11 years—resigned earlier this month as the organization’s senior vice president and chief medical and scientific officer to pursue new opportunities at an as-yet-to-be disclosed major university, many members of the cancer community were surprised and shocked. Brawley had...

How Meaningful Will Changes Be to Ethical Guidelines Following Jose Baselga’s Fall?

In the aftermath of the fall of renowned breast cancer researcher Jose Baselga, MD, PhD, following revelations last month of his failure to disclose millions of dollars in payments from industry, I reached out to learn a little bit more about current institutional conflict of interest policies, especially in light of the current trend promoting academic-governmental-industry collaborations in research. Although...

How a Hollywood-and-Scientist Dream Team Created a New Paradigm in Collaborative Cancer Research

This year marks the 10th anniversary of the launch of Stand Up To Cancer (SU2C)—an enterprise that was at its inception an innovative and somewhat radical concept in cancer research: creating collaborative dream teams of researchers from various disciplines and multiple institutions to put forth the best science that could be translated into treatments for patients within a deadline...

Mike Caligiuri Discusses Upcoming AACR Meeting, Cancer Health Equality, and Sudden Career Change

During last year’s American Association for Cancer Research (AACR) annual meeting in Washington, DC, the association’s president Michael A. Caligiuri, MD, discussed his presidential initiative to further cancer health equality. He said this would include: reducing health disparities; recruiting, retaining, and promoting clinical researchers and scientists from underserved populations; and communicating effectively with survivors and patients about strategies to further...

Why Academia Wasn’t Ready to Build Big Data Systems – A Conversation with Amy Abernethy

Big news hit the pharmaceutical industry in February when Roche Pharmaceuticals announced that it would be acquiring big-data firm Flatiron Health for $1.9 billion. Roche already held a 12% stake in Flatiron, so the total value of the deal--which was completed in early April--will be $2.1 billion, and under the agreement Flatiron would continue its operations as a separate legal...

Eric Rosenthal Reports | A Personal Remembrance of Two Giants of Oncology: Jim and Jimmie Holland

James F. Holland, MD, one of the pioneers of combination chemotherapy and cancer cooperative group research, died at the age of 92 on March 22. His wife, Jimmie C. Holland, MD, who was considered the founder of psycho-oncology, predeceased him by three months on Christmas Eve at age 89. Jim was Distinguished Professor of Neoplastic Diseases at the Icahn School...

right side

ads

Related articles